Singh Samer, Kishore Dhiraj, Singh Rakesh K
Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Department of General Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Front Med (Lausanne). 2022 Mar 2;9:751929. doi: 10.3389/fmed.2022.751929. eCollection 2022.
Fever remains an integral part of acute infectious diseases management, especially for those without effective therapeutics, but the widespread myths about "fevers" and the presence of confusing guidelines from different agencies, which have heightened during the coronavirus disease 2019 (COVID-19) pandemic and are open to alternate interpretation, could deny whole populations the benefits of fever. Guidelines suggesting antipyresis for 37.8-39°C fever are concerning as 39°C boosts the protective heat-shock and immune response (humoral, cell-mediated, and nutritional) whereas ≥40°C initiates/enhances the antiviral responses and restricts high-temperature adapted pathogens, e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), strains of influenza, and measles. Urgent attention is accordingly needed to address the situation because of the potential public health consequences of the existence of conflicting guidelines in the public domain. We have in this article attempted to restate the benefits of fever in disease resolution, dispel myths, and underline the need for alignment of national treatment guidelines with that of the WHO, to promote appropriate practices and reduce the morbidity and mortality from infectious diseases, such as COVID-19.
发热仍然是急性传染病管理中不可或缺的一部分,尤其是对于那些没有有效治疗方法的疾病而言。然而,关于“发热”的广泛误解以及不同机构令人困惑的指南(这些误解和指南在2019冠状病毒病(COVID-19)大流行期间有所加剧,且容易产生不同解读),可能会使全体人群无法从发热中受益。建议对37.8 - 39°C的发热进行退热治疗的指南令人担忧,因为39°C可增强保护性热休克和免疫反应(体液免疫、细胞介导免疫和营养免疫),而≥40°C会启动/增强抗病毒反应并限制适应高温的病原体,例如严重急性呼吸综合征冠状病毒2(SARS-CoV-2)、流感毒株和麻疹病毒。鉴于公共领域存在相互矛盾的指南可能产生的公共卫生后果,因此迫切需要关注这一情况。在本文中,我们试图重申发热在疾病解决中的益处,消除误解,并强调国家治疗指南与世界卫生组织指南保持一致的必要性,以促进恰当的做法并降低诸如COVID-19等传染病的发病率和死亡率。